{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:33:20Z","timestamp":1768080800285,"version":"3.49.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>After decades of research, gene therapy for hemophilia is now commercially available for both hemophilia A and B. Currently, two products, valoctocogene roxaparvovec (for hemophilia A) and etranacogene dezaparvovec (for hemophilia B), have been licensed following approval in the United States and several other countries. Therefore, clinicians must familiarize themselves with these novel treatment options just as they do with other newly available products in order to provide their patients the opportunity to consider which treatment may suit them best. Undoubtedly, gene therapy is a novel platform for treating human disease, and unlike other hemophilia treatments, its biology, mechanisms, and administration logistics are quite complex. Furthermore, additional products using different approaches have entered clinical trials, with more in the preclinical stages of development. This review's aims are (1) to deconstruct gene therapy in hemophilia and provide a basic framework for understanding its components and processes, including the transgene, the vector, and the delivery systems, in order to help clinicians present gene therapy as a treatment option in a shared decision-making model, better understand the clinical data, and explain gene therapy to their patients; (2) to gain knowledge of the currently approved gene therapies for hemophilia A and B, including their eligibility and exclusion criteria and the range of expected outcomes; and (3) to comprehend the shared decision-making process for these therapies and their implementation in clinical practice. In addition, a brief review of the currently approved products and those in clinical trials is presented, followed by a discussion of practical considerations for implementing gene therapy in practice.<\/jats:p>","DOI":"10.1182\/hematology.2025000763","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:10:33Z","timestamp":1764943833000},"page":"659-667","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Deconstructing gene therapy in hemophilia for the clinician"],"prefix":"10.1182","volume":"2025","author":[{"given":"Guy","family":"Young","sequence":"first","affiliation":[{"name":"Children's Hospital Los Angeles, Cancer and Blood Disease Institute, University of Southern California Keck School of Medicine, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"3","key":"2025120616353265100_hem2025000763C1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1538-7836.2006.01776.x","article-title":"Life expectancy in hemophilia outcome","volume":"4","author":"Mejia-Carvajal","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"10040","key":"2025120616353265100_hem2025000763C2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"2025120616353265100_hem2025000763C3","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jtha.2024.04.010","article-title":"Ultra-long factor VIII: a major step towards the hemophilia free mind","volume":"24","author":"Hermans","year":"2024","journal-title":"J Thromb Hemost"},{"issue":"6","key":"2025120616353265100_hem2025000763C4","doi-asserted-by":"crossref","first-page":"e911","DOI":"10.1097\/HS9.0000000000000911","article-title":"Nonfactor therapies for hemophilia","volume":"7","author":"Young","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"2025120616353265100_hem2025000763C5","doi-asserted-by":"crossref","first-page":"e12567","DOI":"10.1002\/rth2.12567","article-title":"Hermans C. Living with a \u201chemophilia-free mind\u201d\u2014the new ambition of hemophilia care?","volume":"5","author":"Krumb","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 6","key":"2025120616353265100_hem2025000763C6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13489","article-title":"Past, present and future of hemophilia gene therapy: from vectors and transgenes to known and unknown outcomes","volume":"4","author":"Pierce","year":"2018","journal-title":"Haemophilia"},{"issue":"1","key":"2025120616353265100_hem2025000763C7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hae.14907","article-title":"Gene therapy for hemophilia A and B, from basic mechanisms to clinical implementation: an illustrated review","volume":"30","author":"Ay","year":"2024","journal-title":"Haemophilia"},{"issue":"2","key":"2025120616353265100_hem2025000763C8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther"},{"issue":"17","key":"2025120616353265100_hem2025000763C9","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"issue":"21","key":"2025120616353265100_hem2025000763C10","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"von Drygalski","year":"2019","journal-title":"Blood Adv"},{"key":"2025120616353265100_hem2025000763C11","first-page":"S1","article-title":"Engineering FVIII for hemophilia gene therapy","volume":"1","author":"Roberts","year":"2011","journal-title":"J Genet Syndrom Gene Ther"},{"key":"2025120616353265100_hem2025000763C12","doi-asserted-by":"crossref","first-page":"14036","DOI":"10.1038\/mtm.2014.36","article-title":"Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver- directed adeno-associated viral vector delivery","volume":"1","author":"Brown","year":"2014","journal-title":"Mol Ther Methods Clin Dev."},{"key":"2025120616353265100_hem2025000763C13","unstructured":"ASC618 gene therapy in hemophilia A patients. ClinicalTrials.gov identifier: NCT04676048. Updated 1February2023. Accessed 30April2025. https:\/\/www.clinicaltrials.gov\/study\/NCT04676048?cond=hemophilia%20A&term=ASC618&rank=1."},{"issue":"5","key":"2025120616353265100_hem2025000763C14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa2410597","volume":"392","author":"Srivastava","year":"2025","journal-title":"N Engl J Med."},{"issue":"1","key":"2025120616353265100_hem2025000763C15","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1038\/s41467-024-51296-8","article-title":"Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice","volume":"15","author":"Sternberg","year":"2024","journal-title":"Nat Commun."},{"issue":"8","key":"2025120616353265100_hem2025000763C16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/hum.1995.6.8-1039","article-title":"Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus- mediated factor IX expression","volume":"6","author":"Fang","year":"1995","journal-title":"Hum Gene Ther"},{"issue":"7-8","key":"2025120616353265100_hem2025000763C17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre- existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"5","key":"2025120616353265100_hem2025000763C18","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ymthe.2024.03.005","article-title":"Autologous gene therapy for hemoglobinopathies: from bench to patient's bedside","volume":"32","author":"Locatelli","year":"2024","journal-title":"Mol Ther"},{"issue":"6","key":"2025120616353265100_hem2025000763C19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2025120616353265100_hem2025000763C20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41587-024-02283-3","article-title":"B cells as drug factories","volume":"42","author":"Sheridan","year":"2024","journal-title":"Nat Biotechnol"},{"key":"2025120616353265100_hem2025000763C21","unstructured":"BeCoMe-9: a clinical study of BE-101 for the treatment of adults with moderately severe or severe hemophilia B. ClinicalTrials.gov identifier: NCT06611436. Updated 20October2025. Accessed 30April2025. https:\/\/clinicaltrials.gov\/study\/NCT06611436?cond=Hemophilia%20B&term=gene%20therapy&aggFilters=status:rec&rank=8."},{"key":"2025120616353265100_hem2025000763C22","unstructured":"A study to investigate the safety and effectiveness of a coagulation factor IX gene insertion therapy (REGV131-LNP1265) in pediatric, adolescent and adult participants with hemophilia B (BEYOND-9). ClinicalTrials.gov identifier: NCT06379789. Updated 23October2025. Accessed April30, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06379789?cond=Hemophilia%20B&term=gene%20therapy&aggFilters=status:rec&rank=4."},{"issue":"11","key":"2025120616353265100_hem2025000763C23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1089\/hum.2017.128","article-title":"Transposons: moving from pre-clinical studies to clinical trials","volume":"28","author":"Tipanee","year":"2017","journal-title":"Hem Gene Ther"},{"key":"2025120616353265100_hem2025000763C24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-genet-040620-022145","article-title":"A field guide to eukaryotic transposable elements","volume":"54","author":"Wells","year":"2020","journal-title":"Annual Rev Genet"},{"issue":"8","key":"2025120616353265100_hem2025000763C25","doi-asserted-by":"crossref","first-page":"e104957","DOI":"10.1371\/journal.pone.0104957","article-title":"Delivery of full-length FVIII using a piggyBac transposon vector to correct a mouse model of hemophilia A","volume":"9","author":"Matsui","year":"2014","journal-title":"PLoS One."},{"key":"2025120616353265100_hem2025000763C26","unstructured":"Hemgenix. Prescribing information. CSL Behring; 2022. Accessed 30April2025. https:\/\/labeling.cslbehring.com\/PI\/US\/Hemgenix\/EN\/Hemgenix-Prescribing-Information.pdf."},{"key":"2025120616353265100_hem2025000763C27","unstructured":"Roctavian. Prescribing information. BioMarin Pharmaceuticals Inc; 2023. Accessed April30, 2025. https:\/\/www.roctavian.com\/en-us\/wp-content\/uploads\/sites\/5\/2023\/07\/ROC-ROCTAVIAN-Prescribing-Information-PI-DIGITAL.pdf?v=0.24."},{"key":"2025120616353265100_hem2025000763C28","unstructured":"Liu\n              A\n            \n          . Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio. Fierce Pharma. Published 21 February 2025. Accessed 1May2025. https:\/\/www.fiercepharma.com\/pharma\/pfizer-empties-gene-therapy-portfolio-discontinues-hemophilia-treatment-beqvez."},{"issue":"11","key":"2025120616353265100_hem2025000763C29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120616353265100_hem2025000763C30","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120616353265100_hem2025000763C31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"New Eng J Med"},{"issue":"8","key":"2025120616353265100_hem2025000763C32","doi-asserted-by":"crossref","first-page":"102615","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 Gene-r8-1 trial","volume":"8","author":"Leavitt","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"issue":"Suppl1","key":"2025120616353265100_hem2025000763C33","article-title":"The phase 3 HOPE-B trial shows 4-year durability of sustained near-normal FIX activity, bleed protection and favourable safety in adults with severe or moderately severe haemophilia B","volume":"31","author":"Leebeek","year":"2025","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"2025120616353265100_hem2025000763C34","first-page":"FP003","article-title":"Efficacy and safety of valoctocogene roxaparvovec for severe hemophilia A 5 years after gene transfer in GENEr8-1","volume":"31","author":"Mahlangu","year":"2025","journal-title":"Haemophilia"},{"issue":"17","key":"2025120616353265100_hem2025000763C35","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and integration analysis of HCC complicated AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2025120616353265100_hem2025000763C36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/hae.14867","article-title":"Delivery of gene therapy in hemophilia treatment centres in the United States: practical aspects of preparedness and implementation","volume":"29","author":"Pipe","year":"2023","journal-title":"Haemophilia"},{"issue":"5","key":"2025120616353265100_hem2025000763C37","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/hae.14822","article-title":"Development of a haemophilia gene therapy shared decision-making tool for clinicians","volume":"29","author":"Limjoco","year":"2023","journal-title":"Haemophilia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/659\/2470396\/659young.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/659\/2470396\/659young.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:35:40Z","timestamp":1765056940000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/659\/556903\/Deconstructing-gene-therapy-in-hemophilia-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000763","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}